Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY 2,627.00
-4.50 (-0.17%)
At close: Dec 2, 2025
Kyowa Kirin Revenue
Kyowa Kirin had revenue of 118.80B JPY in the quarter ending September 30, 2025, a decrease of -8.49%. This brings the company's revenue in the last twelve months to 482.21B, down -3.36% year-over-year. In the year 2024, Kyowa Kirin had annual revenue of 495.56B with 12.06% growth.
Revenue (ttm)
482.21B
Revenue Growth
-3.36%
P/S Ratio
2.85
Revenue / Employee
85.06M
Employees
5,669
Market Cap
1.38T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | 318.35B | 12.53B | 4.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |
Kyowa Kirin News
- 14 days ago - Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting - Benzinga
- 14 days ago - Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting - GlobeNewsWire
- 18 days ago - Kura Oncology wins FDA approval for leukemia drug - Seeking Alpha
- 4 weeks ago - Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region - Business Wire
- 4 weeks ago - Kyowa Kirin reports 9M results - Seeking Alpha
- 4 weeks ago - Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases - GlobeNewsWire
- 5 weeks ago - Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan - GlobeNewsWire
- 5 weeks ago - Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial - Benzinga